Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castrate-resistant prostate cancer: a pooled analysis

Abhiraj Saxena; Marc Yorker; Nicholas A Zorko; Vivek Narayan; Bilal A. Siddiqui; Biren Saraiya; William Tester; Patrick Mille; Amy L. Shaver; Nikita Nikita; Grace L Lu-Yao; Wm Kevin Kelly; Kevin Zarrabi

doi:10.1093/oncolo/oyag172

April 28, 2026The OncologistOpen Access

Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castrate-resistant prostate cancer: a pooled analysis

View Full Paper

Ask AI

Bookmark

Share

Key Points

Quantify frequency and severity of adverse events in T-cell redirecting therapies for mCRPC.
Conducted systematic search of databases for clinical trials on TCEs or CAR-T in mCRPC patients.
Collected and analyzed data on types and frequencies of treatment-related adverse events.
Used a random-effects model for analysis.
Identified thirteen TCE trials with 861 patients and five CAR-T trials with 55 patients.
Cytokine release syndrome occurred in 59% with TCEs and 43% with CAR-T.
Notable neurologic TRAEs in 39% with CAR-T compared to 9% with TCEs (p < 0.0001).
Hematologic and hepatic TRAEs were more frequent with CAR-T compared to TCEs.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Pooled analysis shows high rates of cytokine release syndrome in clinical trials of T-cell therapies for mCRPC, indicating need for better safety strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Saxena et al. (2026) studied this question.

synapsesocial.com/papers/69fbef68164b5133a91a3339 https://doi.org/10.1093/oncolo/oyag172

View Full Paper

Ask AI

Bookmark

Share

Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castrate-resistant prostate cancer: a pooled analysis

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castrate-resistant prostate cancer: a pooled analysis

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading